Dabigatran Versus Warfarin in Patients With Atrial Fibrillation | Zendy

Rangadham Nagarakanti | Zendy; Michael D. Ezekowitz | Zendy; Jonas Oldgren | Zendy; Sean Yang | Zendy; Michael R. Chernick | Zendy; Timothy H. Aikens | Zendy; Greg Flaker | Zendy; Josép Brugada | Zendy; Gabriel Kamenský | Zendy; Amit Parekh | Zendy; Paul Reilly | Zendy; Salim Yusuf | Zendy; Stuart J. Connolly | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation

Author(s) -

Rangadham Nagarakanti,

Michael D. Ezekowitz,

Jonas Oldgren,

Sean Yang,

Michael R. Chernick,

Timothy H. Aikens,

Greg Flaker,

Josép Brugada,

Gabriel Kamenský,

Amit Parekh,

Paul Reilly,

Salim Yusuf,

Stuart J. Connolly

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.977546

Subject(s) - medicine , warfarin , dabigatran , atrial fibrillation , cardioversion , stroke (engine) , cardiology , anesthesia , anticoagulant , randomized controlled trial , mechanical engineering , engineering

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 mg BID (D150) with warfarin for stroke prevention in 18 113 patients with nonvalvular atrial fibrillation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research